Tuesday, May 07 2024
11:32 AM – 11:56 AM ET - Ballroom 2
TCR gene therapy targeting recurrently mutated ""public"" neoantigens
Christopher Klebanoff - MD
Memorial Sloan Kettering Cancer Center
Disclosures: C. Klebanoff: 1; Commercial Interest i.e. Company X; Affini-T Therapeutics. 1; What was received? i.e. Honorarium; Stock options, cash, licensing revenue. 1; For what role? i.e. Speaker; Scientific co-founder, SAB member, sponsored research. 2; Commercial Interest i.e. Company X; Achilles Therapeutics. 2; What was received? i.e. Honorarium; Stock options, cash. 2; For what role? i.e. Speaker; SAB member. 3; Commercial Interest i.e. Company X; Aleta Biotherapeutics. 3; What was received? i.e. Honorarium; Stock options, cash. 3; For what role? i.e. Speaker; SAB member. 4; Commercial Interest i.e. Company X; Catamaran Biotherapeutics. 4; What was received? i.e. Honorarium; Stock options, cash. 4; For what role? i.e. Speaker; SAB member. 5; Commercial Interest i.e. Company X; Obsidian Therapeutics. 5; What was received? i.e. Honorarium; Stock options, cash. 5; For what role? i.e. Speaker; SAB member. 6; Commercial Interest i.e. Company X; Intima Bioscience. 6; What was received? i.e. Honorarium; Licensing revenue. 6; For what role? i.e. Speaker; Sponsored research.